2 results
Approved WMORecruiting
The primary objective of this study is to assess the efficacy of Triumeq versus placebo on overall survival, defined as death from any cause, in participants with ALS at 24 months or after a minimum of 212 events.
Approved WMOCompleted
To demonstrate that Nanocort is safe and effectively reduces the inflammatory signs and symptoms of active GO.